Pharmacokinetics of a Single Subcutaneous Extended‐Release Buprenorphine (Ethiqa XR ) in Healthy Beagles
Journal of Veterinary Pharmacology and Therapeutics · 2026
DOI: 10.1111/jvp.70082 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Veterinary Pharmacology and Therapeutics, 2026. Verfasst von Kornelia Tiffinger und 5 weiteren Autor:innen. Beteiligte Einrichtung: Translational Research in Pain Program, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, USA. Hauptthemen laut MEDLINE: Buprenorphine, Analgesics, Opioid. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fidelis Animal Health, Inc..
Abstract (Originalsprache)
This study evaluated the pharmacokinetics of an extended‐release buprenorphine formulation (Ethiqa XR) in dogs and explored potential sex differences. Twelve healthy intact beagles (6 males and 6 females) received a single subcutaneous injection of Ethiqa XR (0.2 mg/kg). Blood samples were collected up to 168 h post‐administration, and plasma buprenorphine concentrations were measured using liquid chromatography–tandem mass spectrometry. Vital signs, sedation, and nausea scores were recorded. Therapeutic plasma concentrations were sustained for approximately 60–90 h in both sexes, depending on the therapeutic threshold used (0.6 or 1.0 ng/mL). Although no significant differences in pharmacokinetics were detected, drug exposure and elimination were greater in females: median peak plasma buprenorphine concentrations (male: 1.6 ng/mL, female: 2.9 ng/mL); median terminal half‐life (male: 36.6 h, female: 24.7 h); area under the curve (AUC 0–12 h) (male: 12.8 h*ng/mL, female: 16.9 h*ng/mL); AUC (0–96 h) (male: 94.4 h*ng/mL, female: 137.7 h*ng/mL). Time to maximum concentrations were 24 h in both sexes. Higher buprenorphine concentrations were associated with decreased body temperature and heart rate in both sexes and positively correlated with nausea and sedation scores, but only in females. Ethiqa XR administration resulted in therapeutic plasma concentrations up to 90 h, suggesting it may be an alternative option for post‐operative pain control.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Research in Pain Program, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, USA.
- Department of Population Health and Pathobiology, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, USA.
- Department of Anesthesiology, Center for Translational Pain Research, Duke University, Durham, North Carolina, USA.
- Thurston Arthritis Center, University of North Carolina, Chapel Hill, North Carolina, USA.
- Comparative Pain Research and Education Centre, Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, USA.
ORCID-Profile: Kornelia Tiffinger, Hiroko Enomoto
Förderung
- Fidelis Animal Health, Inc.
Zitieren
APA
Tiffinger, K., Enomoto, H., Baynes, R. E., Neumann, L. M., Lascelles, B. D. X., & Enomoto, M. (2026). Pharmacokinetics of a Single Subcutaneous Extended‐Release Buprenorphine (Ethiqa XR ) in Healthy Beagles. Journal of Veterinary Pharmacology and Therapeutics. https://doi.org/10.1111/jvp.70082
Vancouver
Tiffinger K, Enomoto H, Baynes RE, Neumann LM, Lascelles BDX, Enomoto M. Pharmacokinetics of a Single Subcutaneous Extended‐Release Buprenorphine (Ethiqa XR ) in Healthy Beagles. Journal of Veterinary Pharmacology and Therapeutics. 2026. doi:10.1111/jvp.70082
BibTeX
@article{Tiffinger2026,
author = {Tiffinger, Kornelia and Enomoto, Hiroko and Baynes, Ronald E and Neumann, Laura M and Lascelles, B Duncan X and Enomoto, Masataka},
title = {Pharmacokinetics of a Single Subcutaneous Extended‐Release Buprenorphine (Ethiqa XR ) in Healthy Beagles},
journal = {Journal of Veterinary Pharmacology and Therapeutics},
year = {2026},
doi = {10.1111/jvp.70082}
}
EUVIMED